There has been an impressive, little understood increase in cases of Autism Spectrum Disorders (ASD). The lack of any distinctive pathogenetic mechanism has hampered the development of any effective treatments. Increasing evidence indicates oxidative stress, brain inflammation, gastrointestinal (GI) dysfunction and allergic symptoms may be present in ASD patients. The flavone luteolin has antioxidant, anti-flammatory, anti-allergy and neuroprotective properties. Given these findings, a dietary supplement was developed with a unique mixture of luteolin with the related flavonoids quercetin and rutin in a liposomal formulation of olive kernel oil (OKO), which increases their absorption. Results are presented for children with ASD (n=37, 4–14 years old) who had not obtained any benefit from multiple other regimens and who used this formulation for at least 4 months. GI and allergy symptoms improved in about 75% of children, eye contact and attention in 50%, social interaction in 25% and resumption of speech in about 10%. There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness.
JohnsonCPMyersSM. Identification and evaluation of children with autism spectrum disorders. Pediatrics2007; 120(5):1183–215.
2.
GurneyJGMcPheetersMLDavisMM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med2006; 160(8):825–30.
3.
BroadstockMDoughtyCEgglestonM. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism2007; 11(4):335–48.
4.
RogersSJVismaraLA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol2008; 37(1):8–38.
5.
KingBHHollanderESikichL. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry2009; 66(6):583–90.
6.
McPheetersMLWarrenZSatheN. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics2011; 127(5):e1312–21.
7.
BersaniGGherardelliSClementeR. Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol2005; 25(4):372–5.
8.
GalliSJTsaiMPiliponskyAM. The development of allergic inflammation. Nature2008; 454(7203):445–54.
9.
TheoharidesTCAlysandratosKDAngelidouA. Mast cells and inflammation. Biochim Biophys Acta2010; 1822(1):21–33.
10.
TheoharidesTCAngelidouAAlysandratosKD. Mast cell activation and autism. Biochim Biophys Acta2012; 1822(1):34–41.
AngelidouAFrancisKVasiadiM. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation2010; 7:48.
14.
HuangMPangXKaralisKTheoharidesTC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res2003; 59(1):241–9.
15.
AshwoodPWillsSVan de WaterJ. The immune response in autism: A new frontier for autism research. J Leukoc Biol2006; 80(1):1–15.
16.
VargasDLNascimbeneCKrishnanCZimmermanAWPardoCA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol2005; 57(1):67–81.
17.
ChezMGDowlingTPatelPBKhannaPKominskyM. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol2007; 36(6):361–5.
18.
LiXChauhanASheikhAM. Elevated immune response in the brain of autistic patients. J Neuroimmunol2009; 207(1–2):111–6.
19.
SmithSELiJGarbettKMimicsKPattersonPH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci2007; 27(40): 10695–702.
20.
MagalhaesESPinto-MarizFBastos-PintoSPontesATPradoEADeazevedoLC. Immune allergic response in Asperger syndrome. J Neuroimmunol2009;216(1–2):108–12.
21.
AngelidouAAlysandratosKDAsadiS. Brief Report: “Allergic Symptoms” in children with Autism Spectrum Disorders. More than meets the eye?J Autism Dev Disord2011; 41:1579–85.
22.
JyonouchiH. Autism spectrum disorders and allergy: Observation from a pediatric allergy/immunology clinic. Expert Rev Clin Immunol2010; 6(3):397–411.
23.
TheoharidesTC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol2009; 22(4):859–65.
24.
TheoharidesTCBoucherWSpearK. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol2002; 128:344–50.
25.
MiddletonEJr.KandaswamiCTheoharidesTC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev2000; 52:673–751.
26.
KempurajDMadhappanBChristodoulouS. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol2005; 145:934–44.
27.
YaoYWalshWJMcGinnisWRPraticoD. Altered vascular phenotype in autism: Correlation with oxidative stress. Arch Neurol2006; 63(8): 1161–4.
28.
JangSKelleyKWJohnsonRW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA2008; 105(21):7534–9.
29.
SharmaVMishraMGhoshS. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection. Brain Res Bull2007; 73(1–3):55–63.
30.
DirscherlKKarlstetterMEbertS. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation2010;7(1):3.
31.
KempurajDTagenMIliopoulouBP. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol2008; 155:1076–84.
32.
Parker-AthillELuoDBaileyA. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol2009; 217(1–2):20–27.
33.
AsadiSZhangBWengZ.Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol2010; 23(4):1015–20.
34.
KimataMShichijoMMiuraTSerizawaIInagakiNNagaiH. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy2000; 30:501–8.
35.
HaleagraharaNRadhakrishnanALeeNKumarP. Flavonoid quercetin protects against swimming stress-induced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol2009; 621(1–3):46–52.
36.
KumarAGoyalR. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food2008; 11(3):469–73.
37.
ShimoiKOkadaHFurugoriM. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett1998; 438(3):220–4.
38.
HarwoodMnielewska-NikielBBorzellecaJFFlammGWWilliamsGMLinesTC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol2007; 45(11):2179–205.
39.
KawanishiSOikawaSMurataM. Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal2005; 7(11–12):1728–39.
40.
DeBDContiCMSerroniN. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: A review of the current literature. Int J Immunopathol Pharmacol2010; 23(2):417–22.
